Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches
The growing wealth of information regarding the influence that physicochemical characteristics play on nanoparticle biocompatibility and safety is allowing improved design and rationale for their development and preclinical assessment. Accurate and appropriate measurement of these characteristics ac...
Gespeichert in:
| Veröffentlicht in: | Nanomedicine (London, England) England), 2016-06, Vol.11 (11), p.1447-1464 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1464 |
|---|---|
| container_issue | 11 |
| container_start_page | 1447 |
| container_title | Nanomedicine (London, England) |
| container_volume | 11 |
| creator | David, Christopher AW Owen, Andrew Liptrott, Neill J |
| description | The growing wealth of information regarding the influence that physicochemical characteristics play on nanoparticle biocompatibility and safety is allowing improved design and rationale for their development and preclinical assessment. Accurate and appropriate measurement of these characteristics accompanied by informed toxicological assessment is a necessity for the development of safe and effective nanomedicines. While particle type, formulation and mode of administration dictate the individual causes for concern through development, the benefits of nanoformulation for treatment of the diseased state are great. Here we have proposed certain considerations and suggestions, which could lead to better-informed preclinical assessment of nanomaterials for nanomedicine, as well as how this information can and should be extrapolated to the physiological state of the end user. |
| doi_str_mv | 10.2217/nnm-2016-0017 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2321559130</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2321559130</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-3e0de41e571c5863ee1a635c64672c9e41f3a0915d414619bc6162d065017cb93</originalsourceid><addsrcrecordid>eNp1kD1v2zAQhokiQe2mHbsGAjqr4ZEiKWUrnH4ECJAlmQmaOtt0JEohKST-96Ert1smHu-eew94CPkK9DtjoK6870tGQZaUgvpAlqCqupSN5Gd_a16Kum4W5FOMe0pFzYB-JAumQIFUsCTxBhOG3nnnt0XaYRGwM8kNPu7cWKwxvSD6whs_jCYkZzss7M4EY_OWi7kRC-PbwvX95Ic0vDrr0uG6eMLDkes69FucETOOYTB2h_EzOd-YLuKX03tBHn_9fFj9Ke_uf9-uftyVlitIJUfaYgUoFFhRS44IRnJhZSUVs00ebbihDYi2gkpCs7YSJGupFNmEXTf8gnybc_Ph5wlj0vthCj6f1IwzEKIBTjNVzpQNQ4wBN3oMrjfhoIHqo2KdFeujYn1UnPnLU-q07rH9T_9zmoFmBjZTmgJG69Bb1PMvb2RFHt8JfwMLeoyL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2321559130</pqid></control><display><type>article</type><title>Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches</title><source>MEDLINE</source><source>PubMed Central</source><creator>David, Christopher AW ; Owen, Andrew ; Liptrott, Neill J</creator><creatorcontrib>David, Christopher AW ; Owen, Andrew ; Liptrott, Neill J</creatorcontrib><description>The growing wealth of information regarding the influence that physicochemical characteristics play on nanoparticle biocompatibility and safety is allowing improved design and rationale for their development and preclinical assessment. Accurate and appropriate measurement of these characteristics accompanied by informed toxicological assessment is a necessity for the development of safe and effective nanomedicines. While particle type, formulation and mode of administration dictate the individual causes for concern through development, the benefits of nanoformulation for treatment of the diseased state are great. Here we have proposed certain considerations and suggestions, which could lead to better-informed preclinical assessment of nanomaterials for nanomedicine, as well as how this information can and should be extrapolated to the physiological state of the end user.</description><identifier>ISSN: 1743-5889</identifier><identifier>EISSN: 1748-6963</identifier><identifier>DOI: 10.2217/nnm-2016-0017</identifier><identifier>PMID: 27171671</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Acquired immune deficiency syndrome ; AIDS ; Animals ; Apoptosis ; Autophagy ; Biocompatibility ; Cancer ; Chemistry, Pharmaceutical ; Disease ; HIV ; Human immunodeficiency virus ; Humans ; Immune system ; Immune System - drug effects ; Immune System - physiology ; Immunology ; Infections ; Nanomaterials ; Nanomedicine ; Nanoparticles ; Nanoparticles - chemistry ; Nanoparticles - toxicity ; Nanotechnology ; nanotoxicology ; Particle Size ; Pathogens ; Signal transduction ; Surface Properties</subject><ispartof>Nanomedicine (London, England), 2016-06, Vol.11 (11), p.1447-1464</ispartof><rights>Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Jun 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-3e0de41e571c5863ee1a635c64672c9e41f3a0915d414619bc6162d065017cb93</citedby><cites>FETCH-LOGICAL-c371t-3e0de41e571c5863ee1a635c64672c9e41f3a0915d414619bc6162d065017cb93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>313,314,776,780,788,27899,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27171671$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>David, Christopher AW</creatorcontrib><creatorcontrib>Owen, Andrew</creatorcontrib><creatorcontrib>Liptrott, Neill J</creatorcontrib><title>Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches</title><title>Nanomedicine (London, England)</title><addtitle>Nanomedicine (Lond)</addtitle><description>The growing wealth of information regarding the influence that physicochemical characteristics play on nanoparticle biocompatibility and safety is allowing improved design and rationale for their development and preclinical assessment. Accurate and appropriate measurement of these characteristics accompanied by informed toxicological assessment is a necessity for the development of safe and effective nanomedicines. While particle type, formulation and mode of administration dictate the individual causes for concern through development, the benefits of nanoformulation for treatment of the diseased state are great. Here we have proposed certain considerations and suggestions, which could lead to better-informed preclinical assessment of nanomaterials for nanomedicine, as well as how this information can and should be extrapolated to the physiological state of the end user.</description><subject>Acquired immune deficiency syndrome</subject><subject>AIDS</subject><subject>Animals</subject><subject>Apoptosis</subject><subject>Autophagy</subject><subject>Biocompatibility</subject><subject>Cancer</subject><subject>Chemistry, Pharmaceutical</subject><subject>Disease</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immune system</subject><subject>Immune System - drug effects</subject><subject>Immune System - physiology</subject><subject>Immunology</subject><subject>Infections</subject><subject>Nanomaterials</subject><subject>Nanomedicine</subject><subject>Nanoparticles</subject><subject>Nanoparticles - chemistry</subject><subject>Nanoparticles - toxicity</subject><subject>Nanotechnology</subject><subject>nanotoxicology</subject><subject>Particle Size</subject><subject>Pathogens</subject><subject>Signal transduction</subject><subject>Surface Properties</subject><issn>1743-5889</issn><issn>1748-6963</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kD1v2zAQhokiQe2mHbsGAjqr4ZEiKWUrnH4ECJAlmQmaOtt0JEohKST-96Ert1smHu-eew94CPkK9DtjoK6870tGQZaUgvpAlqCqupSN5Gd_a16Kum4W5FOMe0pFzYB-JAumQIFUsCTxBhOG3nnnt0XaYRGwM8kNPu7cWKwxvSD6whs_jCYkZzss7M4EY_OWi7kRC-PbwvX95Ic0vDrr0uG6eMLDkes69FucETOOYTB2h_EzOd-YLuKX03tBHn_9fFj9Ke_uf9-uftyVlitIJUfaYgUoFFhRS44IRnJhZSUVs00ebbihDYi2gkpCs7YSJGupFNmEXTf8gnybc_Ph5wlj0vthCj6f1IwzEKIBTjNVzpQNQ4wBN3oMrjfhoIHqo2KdFeujYn1UnPnLU-q07rH9T_9zmoFmBjZTmgJG69Bb1PMvb2RFHt8JfwMLeoyL</recordid><startdate>20160601</startdate><enddate>20160601</enddate><creator>David, Christopher AW</creator><creator>Owen, Andrew</creator><creator>Liptrott, Neill J</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20160601</creationdate><title>Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches</title><author>David, Christopher AW ; Owen, Andrew ; Liptrott, Neill J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-3e0de41e571c5863ee1a635c64672c9e41f3a0915d414619bc6162d065017cb93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>AIDS</topic><topic>Animals</topic><topic>Apoptosis</topic><topic>Autophagy</topic><topic>Biocompatibility</topic><topic>Cancer</topic><topic>Chemistry, Pharmaceutical</topic><topic>Disease</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immune system</topic><topic>Immune System - drug effects</topic><topic>Immune System - physiology</topic><topic>Immunology</topic><topic>Infections</topic><topic>Nanomaterials</topic><topic>Nanomedicine</topic><topic>Nanoparticles</topic><topic>Nanoparticles - chemistry</topic><topic>Nanoparticles - toxicity</topic><topic>Nanotechnology</topic><topic>nanotoxicology</topic><topic>Particle Size</topic><topic>Pathogens</topic><topic>Signal transduction</topic><topic>Surface Properties</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>David, Christopher AW</creatorcontrib><creatorcontrib>Owen, Andrew</creatorcontrib><creatorcontrib>Liptrott, Neill J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Nanomedicine (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>David, Christopher AW</au><au>Owen, Andrew</au><au>Liptrott, Neill J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches</atitle><jtitle>Nanomedicine (London, England)</jtitle><addtitle>Nanomedicine (Lond)</addtitle><date>2016-06-01</date><risdate>2016</risdate><volume>11</volume><issue>11</issue><spage>1447</spage><epage>1464</epage><pages>1447-1464</pages><issn>1743-5889</issn><eissn>1748-6963</eissn><abstract>The growing wealth of information regarding the influence that physicochemical characteristics play on nanoparticle biocompatibility and safety is allowing improved design and rationale for their development and preclinical assessment. Accurate and appropriate measurement of these characteristics accompanied by informed toxicological assessment is a necessity for the development of safe and effective nanomedicines. While particle type, formulation and mode of administration dictate the individual causes for concern through development, the benefits of nanoformulation for treatment of the diseased state are great. Here we have proposed certain considerations and suggestions, which could lead to better-informed preclinical assessment of nanomaterials for nanomedicine, as well as how this information can and should be extrapolated to the physiological state of the end user.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>27171671</pmid><doi>10.2217/nnm-2016-0017</doi><tpages>18</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1743-5889 |
| ispartof | Nanomedicine (London, England), 2016-06, Vol.11 (11), p.1447-1464 |
| issn | 1743-5889 1748-6963 |
| language | eng |
| recordid | cdi_proquest_journals_2321559130 |
| source | MEDLINE; PubMed Central |
| subjects | Acquired immune deficiency syndrome AIDS Animals Apoptosis Autophagy Biocompatibility Cancer Chemistry, Pharmaceutical Disease HIV Human immunodeficiency virus Humans Immune system Immune System - drug effects Immune System - physiology Immunology Infections Nanomaterials Nanomedicine Nanoparticles Nanoparticles - chemistry Nanoparticles - toxicity Nanotechnology nanotoxicology Particle Size Pathogens Signal transduction Surface Properties |
| title | Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T00%3A03%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Determining%20the%20relationship%20between%20nanoparticle%20characteristics%20and%20immunotoxicity:%20key%20challenges%20and%20approaches&rft.jtitle=Nanomedicine%20(London,%20England)&rft.au=David,%20Christopher%20AW&rft.date=2016-06-01&rft.volume=11&rft.issue=11&rft.spage=1447&rft.epage=1464&rft.pages=1447-1464&rft.issn=1743-5889&rft.eissn=1748-6963&rft_id=info:doi/10.2217/nnm-2016-0017&rft_dat=%3Cproquest_cross%3E2321559130%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2321559130&rft_id=info:pmid/27171671&rfr_iscdi=true |